abstract: Anticoagulant rodenticides (ARs) are commonly used to control rodent infestations for biocidal and plant protection purposes. This can lead to @entity1 exposure of non-target small mammals and their predators, which is known from several regions of the world. However, drivers of exposure variation are usually not known. To identify environmental drivers of @entity1 exposure in non-targets we analyzed 331 liver samples of red foxes ( @entity3 ) for residues of eight ARs and used local parameters (percentage of urban area and livestock density) to test for associations to residue occurrence. 59.8% of samples collected across Germany contained at least one rodenticide, in 20.2% of cases at levels at which biological effects are suspected. Second generation anticoagulants (mainly brodifacoum and @entity2 ) occurred more often than first generation anticoagulants. Local livestock density and the percentage of urban area were good indicators for @entity1 residue occurrence. There was a positive association between pooled ARs and brodifacoum occurrence with livestock density as well as of pooled ARs, brodifacoum and difenacoum occurrence with the percentage of urban area on administrative district level. @entity0 holding drove associations of livestock density to @entity1 residue occurrence in foxes. Therefore, risk mitigation strategies should focus on areas of high @entity0 density and on highly urbanized areas to minimize non-target risk.

title: Relation between Intensity of Biocide Practice and Residues of Anticoagulant Rodenticides in Red Foxes ( XXXX ).

answer: @entity3


abstract: UNASSIGNED: OBJECT Endoscopic third ventriculostomy (ETV) is the treatment of choice for obstructive @entity1 ; however, the success of ETV in @entity0 who have previously undergone shunt placement remains unclear. The present study analyzed 103 adult @entity0 with @entity1 who underwent ETV for obstructive @entity1 and evaluated the effect of previous shunt placement on post-ETV outcomes. METHODS This study was a retrospective review of 151 consecutive @entity0 who were treated between 2007 and 2013 with ETV for @entity1 . One hundred three (68.2%) @entity0 with @entity1 causing obstructive @entity1 were included in the analysis. Postoperative ETV patency and aqueductal and cisternal flow were assessed by high-resolution, gradient-echo MRI. Post-ETV Mini-Mental State Examination, Timed Up and Go, and Tinetti scores were compared with preoperative values. Univariate and multivariate analyses were performed comparing the post-ETV outcomes in @entity0 who underwent a primary (no previous shunt) ETV (n = 64) versus secondary (previous shunt) ETV (n = 39). RESULTS The majority of @entity0 showed significant improvement in symptoms after ETV; however, no significant differences were seen in any of the quantitative tests performed during follow-up. Symptom recurrence occurred in 29 (28.2%) @entity0 after ETV, after a median of 3.0 (interquartile range 0.8-8.0) months post-ETV failure. Twenty-seven (26.2%) @entity0 required surgical revision after their initial ETV. @entity0 who received a secondary ETV had higher rates of symptom recurrence (p = 0.003) and surgical revision (p = 0.003), particularly in regard to additional shunt placement/revision post-ETV (p = 0.005). These differences remained significant after multivariate analysis for both symptom recurrence (p = 0.030) and surgical revision (p = 0.043). CONCLUSIONS @entity0 with obstructive @entity1 due to @entity1 exhibit symptomatic improvement after ETV, with a relatively low failure rate. @entity0 with a primary history of shunt placement who undergo ETV as a secondary intervention are at increased risk of symptom recurrence and need for surgical revision post-ETV.

title: Lower rates of symptom recurrence and surgical revision after primary compared with secondary endoscopic third ventriculostomy for obstructive XXXX secondary to @entity1 in adults.

answer: @entity1


abstract: UNASSIGNED: OBJECT Endoscopic third ventriculostomy (ETV) is the treatment of choice for obstructive @entity1 ; however, the success of ETV in @entity0 who have previously undergone shunt placement remains unclear. The present study analyzed 103 adult @entity0 with @entity1 who underwent ETV for obstructive @entity1 and evaluated the effect of previous shunt placement on post-ETV outcomes. METHODS This study was a retrospective review of 151 consecutive @entity0 who were treated between 2007 and 2013 with ETV for @entity1 . One hundred three (68.2%) @entity0 with @entity1 causing obstructive @entity1 were included in the analysis. Postoperative ETV patency and aqueductal and cisternal flow were assessed by high-resolution, gradient-echo MRI. Post-ETV Mini-Mental State Examination, Timed Up and Go, and Tinetti scores were compared with preoperative values. Univariate and multivariate analyses were performed comparing the post-ETV outcomes in @entity0 who underwent a primary (no previous shunt) ETV (n = 64) versus secondary (previous shunt) ETV (n = 39). RESULTS The majority of @entity0 showed significant improvement in symptoms after ETV; however, no significant differences were seen in any of the quantitative tests performed during follow-up. Symptom recurrence occurred in 29 (28.2%) @entity0 after ETV, after a median of 3.0 (interquartile range 0.8-8.0) months post-ETV failure. Twenty-seven (26.2%) @entity0 required surgical revision after their initial ETV. @entity0 who received a secondary ETV had higher rates of symptom recurrence (p = 0.003) and surgical revision (p = 0.003), particularly in regard to additional shunt placement/revision post-ETV (p = 0.005). These differences remained significant after multivariate analysis for both symptom recurrence (p = 0.030) and surgical revision (p = 0.043). CONCLUSIONS @entity0 with obstructive @entity1 due to @entity1 exhibit symptomatic improvement after ETV, with a relatively low failure rate. @entity0 with a primary history of shunt placement who undergo ETV as a secondary intervention are at increased risk of symptom recurrence and need for surgical revision post-ETV.

title: Lower rates of symptom recurrence and surgical revision after primary compared with secondary endoscopic third ventriculostomy for obstructive @entity1 secondary to XXXX in adults.

answer: @entity1


abstract: BACKGROUND: Septic @entity1 is one of the most common complications in @entity9 @entity0 with a high risk of developing @entity8 ( @entity8 ). Emerging data indicate that @entity0 target of rapamyci ( @entity11 ) signaling plays a major role in septic @entity3 by regulating the immune response of macrophage. This study was designed to evaluate the role of @entity11 signaling in kidney macrophages during @entity12 -induced chronic @entity1 and subsequent fibrogenesis. METHODS: Male C57BL/6 @entity2 were used for all animal studies (n = 9 for each group). Lipopolysaccharide ( @entity14 ) was injected intraperitoneally (1 mg/kg) every 2 days to induce persistent @entity12 . @entity10 (1 mg/kg  day) was administered to a subgroup of @entity2 1 day prior to @entity14 treatment and continued to termination of the experiment. In ex-vivo experiment, RAW264.7 cells were cultured and treated with @entity14 (2   g/ml) for 48 h while a subgroup of cells were incubated in the presence of @entity10 (50 nmol) for 2 h. RESULTS: Continuous administration of @entity14 resulted in progressive macrophage infiltration, tubular injury and collagen deposition in @entity2 kidneys. @entity10 markedly ameliorated @entity14 -induced kidney pathological changes. Expression of pS6K was rarely observed in normal kidney macrophages, but significantly increased with time by @entity14 treatment. In ex-vivo study, @entity14 induced prominent production of @entity7 and @entity13 in cultured RAW264.7 cells, which was significantly suppressed by @entity10 . CONCLUSION: Taken together, our findings show that @entity12 results in activation of @entity11 signaling in macrophages, leading to progressive kidney inflammatory @entity5 and subsequent @entity4 . Our study may reveal a mechanism involved in the development of @entity6 -associated @entity8 and @entity1 .

title: Lipopolysaccharide Induces @entity8 and XXXX through Activation of @entity11 Signaling in Macrophages.

answer: @entity4


abstract: BACKGROUND: Septic @entity1 is one of the most common complications in @entity9 @entity0 with a high risk of developing @entity8 ( @entity8 ). Emerging data indicate that @entity0 target of rapamyci ( @entity11 ) signaling plays a major role in septic @entity3 by regulating the immune response of macrophage. This study was designed to evaluate the role of @entity11 signaling in kidney macrophages during @entity12 -induced chronic @entity1 and subsequent fibrogenesis. METHODS: Male C57BL/6 @entity2 were used for all animal studies (n = 9 for each group). Lipopolysaccharide ( @entity14 ) was injected intraperitoneally (1 mg/kg) every 2 days to induce persistent @entity12 . @entity10 (1 mg/kg  day) was administered to a subgroup of @entity2 1 day prior to @entity14 treatment and continued to termination of the experiment. In ex-vivo experiment, RAW264.7 cells were cultured and treated with @entity14 (2   g/ml) for 48 h while a subgroup of cells were incubated in the presence of @entity10 (50 nmol) for 2 h. RESULTS: Continuous administration of @entity14 resulted in progressive macrophage infiltration, tubular injury and collagen deposition in @entity2 kidneys. @entity10 markedly ameliorated @entity14 -induced kidney pathological changes. Expression of pS6K was rarely observed in normal kidney macrophages, but significantly increased with time by @entity14 treatment. In ex-vivo study, @entity14 induced prominent production of @entity7 and @entity13 in cultured RAW264.7 cells, which was significantly suppressed by @entity10 . CONCLUSION: Taken together, our findings show that @entity12 results in activation of @entity11 signaling in macrophages, leading to progressive kidney inflammatory @entity5 and subsequent @entity4 . Our study may reveal a mechanism involved in the development of @entity6 -associated @entity8 and @entity1 .

title: Lipopolysaccharide Induces @entity8 and @entity4 through Activation of XXXX Signaling in Macrophages.

answer: @entity11


abstract: BACKGROUND: Septic @entity1 is one of the most common complications in @entity9 @entity0 with a high risk of developing @entity8 ( @entity8 ). Emerging data indicate that @entity0 target of rapamyci ( @entity11 ) signaling plays a major role in septic @entity3 by regulating the immune response of macrophage. This study was designed to evaluate the role of @entity11 signaling in kidney macrophages during @entity12 -induced chronic @entity1 and subsequent fibrogenesis. METHODS: Male C57BL/6 @entity2 were used for all animal studies (n = 9 for each group). Lipopolysaccharide ( @entity14 ) was injected intraperitoneally (1 mg/kg) every 2 days to induce persistent @entity12 . @entity10 (1 mg/kg  day) was administered to a subgroup of @entity2 1 day prior to @entity14 treatment and continued to termination of the experiment. In ex-vivo experiment, RAW264.7 cells were cultured and treated with @entity14 (2   g/ml) for 48 h while a subgroup of cells were incubated in the presence of @entity10 (50 nmol) for 2 h. RESULTS: Continuous administration of @entity14 resulted in progressive macrophage infiltration, tubular injury and collagen deposition in @entity2 kidneys. @entity10 markedly ameliorated @entity14 -induced kidney pathological changes. Expression of pS6K was rarely observed in normal kidney macrophages, but significantly increased with time by @entity14 treatment. In ex-vivo study, @entity14 induced prominent production of @entity7 and @entity13 in cultured RAW264.7 cells, which was significantly suppressed by @entity10 . CONCLUSION: Taken together, our findings show that @entity12 results in activation of @entity11 signaling in macrophages, leading to progressive kidney inflammatory @entity5 and subsequent @entity4 . Our study may reveal a mechanism involved in the development of @entity6 -associated @entity8 and @entity1 .

title: Lipopolysaccharide Induces XXXX and @entity4 through Activation of @entity11 Signaling in Macrophages.

answer: @entity8


abstract: OBJECTIVE: To investigate the feasibility of adipose-derived mesenchymal stem cells (ADMSCs) differentiating into corneal epithelium-like cells after transfection with @entity2 gene. METHODS: The adipose tissue from bilateral inguinal of healthy C57BL/6 @entity0 (5-6 weeks old) was used to isolate and culture ADMSCs. The 3rd passage ADMSCs were subjected to treatments of non-transfection (group A), pcDNA3.1 empty vector transfection (group B), and recombinant plasmid of pcDNA3.1- @entity2 transfection (group C), respectively. At 48 hours after transfection, the cells in groups B and C were selected with G418. The cell morphology changes were observed under the inverted microscope. @entity2 protein and level of corneal epithelial cells specific @entity3 ( @entity3 ) were measured by Western blot. Real-time fluorescence quantitative PCR was applied to measure the mRNA expression of @entity3 . RESULTS: No morphology change was observed in groups A and B. Two different cell clones were found in group C. No.1 selected clone showed a flagstone-like appearance that was similar to that of corneal epithelial cells; No.2 selected clone showed a net-like appearance, with 3-7 cell processes. The Western blot results showed the @entity2 protein expression in 2 clones of group C, but no expression in groups A and B; and @entity3 protein expression was only observed in No.1 selected clone of group C, and no expression in the others. The real-time fluorescence quantitative PCR results showed that the @entity3 mRNA expression level of No.1 selected clone of group C was 8.64    0.73, which was significantly higher than that of No.2 selected clone of group C (0.55    0.42), group B (1.36    0.40), and group A (1.00    0.00) (P < 0.05), and there was no significant difference among groups A, Band No.2 selected clone of group C (P > 0.05). CONCLUSION: @entity2 gene transfection could induce differentiation of ADMSCs into corneal epithelium-like cells which express @entity3 at both the mRNA and protein levels. This result provides a promising strategy of generating corneal epithelium-like cells for construction of tissue engineered @entity1 .

title: [Differentiation of adipose-derived mesenchymal stem cells after transfection with XXXX gene].

answer: @entity2


abstract: BACKGROUND: The ventriculoscopic approach has been considered to be more safe and effective in the treatment of @entity3 , @entity1 and @entity4 in neurosurgery. We found that intraoperative bleeding-related complications have the greatest impact on ventriculoscopic surgery. Until now, few studies fully discussed this complication. METHODS: @entity0 who underwent ventriculoscopic surgery between May 2011 and December 2012 at Beijing Tiantan Hospital were analyzed. RESULTS: A total of 126 @entity0 were enrolled in the study. @entity2 was observed in 75 cases (59.5%). @entity2 classification of @entity0 was as follows: stage I (n  = 62); stage II (n  = 11); stage III (n  = 2). We found that there was no significant difference in complication rate and rate of symptom improvement between the @entity0 who had @entity2 and the @entity0 who did not (P < 0.05). CONCLUSIONS: @entity2 in ventriculoscopic surgery should be paid more attention. Generally, a skilled neurosurgeon can address @entity2 with a low complication rate. Consequently, the ventriculoscopic approach is safe and effective in the treatment of specified @entity5 .

title: XXXX in Ventriculoscopic Surgery: Experience of a Single Chinese Neurosurgery Center.

answer: @entity2


abstract: PURPOSE: The aim of this study was to evaluate the outcomes of total skin electron beam therapy (TSEBT) with "translational technique" in the management of @entity7 ( @entity7 ). METHODS: Between January 1995 and October 2014, 51 @entity0 with @entity7 were treated using TSEBT with translational technique. The total dose was 2800-3600 cGy, de-livered in 7 to 20 fractions. Out of the total 51 @entity0 , 22 (43.1%) had T2 (generalized patch/plaque) disease, 20 (39.3%) had T3 disease ( @entity1 stage), and 9 (17.6%) had @entity2 . Radiation-related late @entity5 parameters including @entity4 , pigmentation changes, hair loss, @entity8 and @entity6 were assessed according to RTOG/EORTC Late Radiation Morbidity Scoring Schema after at least 3 months from TSEBT. RESULTS: Treatment response was categorized as complete remission (CR), partial remission (PR), or non-responding (NR) lesions. After TSEBT with translational technique, CR rate was 68.6% and PR rate 23.5%, while the NR rate was 7.9%. Overall, the rates of grade 1, grade 2, grade 3, and grade 4 @entity3 were 17.6% )9 @entity0 ), 39.3% (20 @entity0 ), 35.3% (18 @entity0 ), and 7.8% (4 @entity0 ), respectively. At a median follow-up of 79 months (range 14-142), overall survival (OS) and disease-free survival (DFS) rates were 83% and 46%, respectively. CONCLUSION: For @entity0 with @entity7 refractory to topical chemotherapy and phototherapy, TSEBT with translational technique offers excellent local control (LC: CR+PR) and favorable OS rates along with substantial relief of symptoms.

title: Evaluation of XXXX management by total skin electron beam therapy with "translational technique".

answer: @entity7


abstract: PURPOSE: Managing severe @entity1 early has several benefits. Correct early management includes delivering an appropriate fluid challenge. The purpose of this paper is to assess whether junior doctors prescribe adequate fluid challenges to severely septic @entity0 . DESIGN/METHODOLOGY/APPROACH: A questionnaire outlining three scenarios, each involving a @entity0 with severe @entity1 , but with varying weights (50/75/100 kg), was distributed to junior doctors, working in two UK hospitals, managing surgical @entity0 . @entity0 were asked the fluid volume challenge that they would prescribe for each @entity0 . Responses were compared with the Surviving Sepsis Campaign's recommended volume during the study (20 ml/kg). FINDINGS: Totally, 77 questionnaires were completed. There were 15/231 (6.5 per cent) correct responses. The median volume chosen in each scenario was 500 ml, equating to 5-10 ml/kg. There was no significant difference between doctor grades ( @entity2 ) in any scenario. With most junior doctors (FY1), there was no difference in responses according to weight; for SHOs the only significant difference was between the 75 and 100 kg scenarios. PRACTICAL IMPLICATIONS: Junior doctors are not following guidelines when prescribing fluid challenges to severely septic @entity0 , giving too little and not adjusting volume according to body weight. This implies that high-prevalence, high-mortality conditions are not being treated appropriately by those most likely to treat these @entity0 . More teaching, training and reassessment is required to improve care. ORIGINALITY/VALUE: This, the first case-based survey the authors could find, highlights an issue requiring significant improvement. The implications are likely to be relevant to clinicians in all UK hospitals.

title: Are adequate fluid challenges prescribed for severe XXXX ?

answer: @entity1


abstract: BACKGROUND: Anterior cervical decompression and fusion (ACDF) has long been the preferred treatment for @entity3 ( @entity3 ). However, few studies have focused on surgical results of @entity3 in @entity0 with developmental canal @entity2 ( @entity4 ). The purpose of this study was to investigate @entity4 as a comorbidity in @entity0 with @entity3 and the correlation between surgical results and @entity4 . METHODS: From January 1995 to December 2005, 122 @entity0 treated with ACDF for @entity3 were enrolled in this retrospective study. Pavlov's ratio was used to evaluate cervical spinal canal size, with a value of   <   0.82 at least one level indicating @entity4 . @entity0 were divided into two groups: those with @entity4 preoperatively ( @entity4 group, n   =   50 [41.0  %]) and those without @entity4 ( @entity4 , n   =   72). Clinical data and radiological parameters were compared between groups. RESULTS: There were no significant differences in preoperative and 2-year follow-up Japanese Orthopedic Association scores between groups. Both groups achieved satisfactory fusion rates ( @entity4 , 92.0  %; non- @entity4 , 93.0  %). @entity1 ( @entity1 ) was detected in 66.0  % of @entity0 in the @entity4 group and in 43.0  % of @entity0 in the @entity4 (p   =   0.01). However, there was no significant difference in the incidence of @entity1 requiring surgery between groups (p   =   0.20). DISCUSSION: @entity4 is a common comorbidity in @entity0 with @entity3 . The findings of this study have added knowledge on the correlation between @entity4 and @entity1 after anterior fusion surgery. CONCLUSIONS: @entity4 did not affect neurologic improvement postoperatively at short-term follow-up. Although @entity4 increased the incidence of @entity1 after anterior fusion, it did not predict @entity1 requiring surgery. Therefore, @entity0 with @entity4 must receive close follow-up.

title: Relationship between developmental canal XXXX and surgical results of anterior decompression and fusion in @entity0 with @entity3 .

answer: @entity2


abstract: BACKGROUND: Anterior cervical decompression and fusion (ACDF) has long been the preferred treatment for @entity3 ( @entity3 ). However, few studies have focused on surgical results of @entity3 in @entity0 with developmental canal @entity2 ( @entity4 ). The purpose of this study was to investigate @entity4 as a comorbidity in @entity0 with @entity3 and the correlation between surgical results and @entity4 . METHODS: From January 1995 to December 2005, 122 @entity0 treated with ACDF for @entity3 were enrolled in this retrospective study. Pavlov's ratio was used to evaluate cervical spinal canal size, with a value of   <   0.82 at least one level indicating @entity4 . @entity0 were divided into two groups: those with @entity4 preoperatively ( @entity4 group, n   =   50 [41.0  %]) and those without @entity4 ( @entity4 , n   =   72). Clinical data and radiological parameters were compared between groups. RESULTS: There were no significant differences in preoperative and 2-year follow-up Japanese Orthopedic Association scores between groups. Both groups achieved satisfactory fusion rates ( @entity4 , 92.0  %; non- @entity4 , 93.0  %). @entity1 ( @entity1 ) was detected in 66.0  % of @entity0 in the @entity4 group and in 43.0  % of @entity0 in the @entity4 (p   =   0.01). However, there was no significant difference in the incidence of @entity1 requiring surgery between groups (p   =   0.20). DISCUSSION: @entity4 is a common comorbidity in @entity0 with @entity3 . The findings of this study have added knowledge on the correlation between @entity4 and @entity1 after anterior fusion surgery. CONCLUSIONS: @entity4 did not affect neurologic improvement postoperatively at short-term follow-up. Although @entity4 increased the incidence of @entity1 after anterior fusion, it did not predict @entity1 requiring surgery. Therefore, @entity0 with @entity4 must receive close follow-up.

title: Relationship between developmental canal @entity2 and surgical results of anterior decompression and fusion in @entity0 with XXXX .

answer: @entity3


abstract: BACKGROUND: Anterior cervical decompression and fusion (ACDF) has long been the preferred treatment for @entity3 ( @entity3 ). However, few studies have focused on surgical results of @entity3 in @entity0 with developmental canal @entity2 ( @entity4 ). The purpose of this study was to investigate @entity4 as a comorbidity in @entity0 with @entity3 and the correlation between surgical results and @entity4 . METHODS: From January 1995 to December 2005, 122 @entity0 treated with ACDF for @entity3 were enrolled in this retrospective study. Pavlov's ratio was used to evaluate cervical spinal canal size, with a value of   <   0.82 at least one level indicating @entity4 . @entity0 were divided into two groups: those with @entity4 preoperatively ( @entity4 group, n   =   50 [41.0  %]) and those without @entity4 ( @entity4 , n   =   72). Clinical data and radiological parameters were compared between groups. RESULTS: There were no significant differences in preoperative and 2-year follow-up Japanese Orthopedic Association scores between groups. Both groups achieved satisfactory fusion rates ( @entity4 , 92.0  %; non- @entity4 , 93.0  %). @entity1 ( @entity1 ) was detected in 66.0  % of @entity0 in the @entity4 group and in 43.0  % of @entity0 in the @entity4 (p   =   0.01). However, there was no significant difference in the incidence of @entity1 requiring surgery between groups (p   =   0.20). DISCUSSION: @entity4 is a common comorbidity in @entity0 with @entity3 . The findings of this study have added knowledge on the correlation between @entity4 and @entity1 after anterior fusion surgery. CONCLUSIONS: @entity4 did not affect neurologic improvement postoperatively at short-term follow-up. Although @entity4 increased the incidence of @entity1 after anterior fusion, it did not predict @entity1 requiring surgery. Therefore, @entity0 with @entity4 must receive close follow-up.

title: Relationship between developmental canal @entity2 and surgical results of anterior decompression and fusion in XXXX with @entity3 .

answer: @entity0


abstract: BACKGROUND: Before introducing long-term @entity1 ( @entity1 ) risk models in clinical practice, their external validity should be investigated. We assessed the validity of the CArdiovascular Monitoring Unit in Northern Italy (CAMUNI) 20-year risk score, developed in Northern Italy, and published previously, when applied to a population with different risk factors distribution and event incidence. METHODS: The validation sample consisted of 5307 35-69 year-old subjects (2418 @entity0 ) enrolled in Central Italy during the 1980s ( @entity2 Istituto Superiore di Sanit   (MATISS) study). Baseline risk factor assessment and follow-up procedures, including MONICA definition of acute events, followed a shared protocol with the derivation cohorts. We estimated model calibration and discrimination (area under the ROC curve, AUC) in the validation set; as well as the net benefit of using the CAMUNI risk score as second-level screening in subjects at different levels of short-term risk. RESULTS: The 20-year risk of event was 14% in @entity0 and 7% in @entity0 . Model calibration was satisfactory, and the strength of the association between predictors and the endpoint was the same as in the derivation population. The AUC was 0.734 ( @entity0 ) and 0.802 ( @entity0 ). The net benefit of the CAMUNI score was 3.9 (95% confidence interval: 2.1-5.7) and 2.9 (1.7-4.3) in @entity0 and @entity0 at low 10-year risk, respectively. Among subjects at high short-term risk, a significant net benefit of 9.8 was observed in @entity0 only. A pooled CAMUNI-MATISS risk score is provided. CONCLUSIONS: In this low-incidence European population, long-term @entity1 prediction through the CAMUNI risk score is accurate and it has the potential to improve current primary prevention strategies based on short-term risk scores alone.

title: Validity of a long-term XXXX risk prediction equation for low-incidence populations: The CAMUNI-MATISS Cohorts Collaboration Study.

answer: @entity1


abstract: BACKGROUND: Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction and abnormal bile flow ultimately results in the development of @entity4 . This condition peaks in adolescence with up to 20% of adolescents with @entity5 developing @entity3 . Early changes in the liver may ultimately result in @entity6 with @entity0 needing transplantation. One therapeutic option currently used is @entity7 . OBJECTIVES: To analyse evidence that @entity7 improves indices of liver function, reduces the risk of developing @entity3 and improves outcomes in general in @entity5 . SEARCH METHODS: We searched the Cochrane @entity5 and @entity1 Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also contacted drug companies.Date of the most recent search of the Group's trials register: 29 May 2014. SELECTION CRITERIA: Randomised controlled trials of the use of @entity7 for at least three months compared with placebo or no additional treatment in @entity0 with @entity5 . DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial eligibility and quality. MAIN RESULTS: Ten trials have been identified, of which three trials involving 118 @entity0 were included; the dose of @entity7 ranged from 10 to 20 mg/kg/day for up to 12 months. The complex design used in two trials meant that data could only be analysed for subsets of @entity0 . There was no significant difference in weight change, mean difference -0.90 kg (95% confidence interval -1.94 to 0.14) based on 30 @entity0 from two trials. Improvement in biliary excretion was reported in only one trial and no significant change after treatment was shown. There were no data available for analysis for long-term outcomes such as @entity2 or need for liver transplantation. AUTHORS' CONCLUSIONS: There are few trials assessing the effectiveness of @entity7 . There is insufficient evidence to justify its routine use in @entity5 .

title: XXXX for @entity4 .

answer: @entity7


abstract: BACKGROUND: Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction and abnormal bile flow ultimately results in the development of @entity4 . This condition peaks in adolescence with up to 20% of adolescents with @entity5 developing @entity3 . Early changes in the liver may ultimately result in @entity6 with @entity0 needing transplantation. One therapeutic option currently used is @entity7 . OBJECTIVES: To analyse evidence that @entity7 improves indices of liver function, reduces the risk of developing @entity3 and improves outcomes in general in @entity5 . SEARCH METHODS: We searched the Cochrane @entity5 and @entity1 Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also contacted drug companies.Date of the most recent search of the Group's trials register: 29 May 2014. SELECTION CRITERIA: Randomised controlled trials of the use of @entity7 for at least three months compared with placebo or no additional treatment in @entity0 with @entity5 . DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial eligibility and quality. MAIN RESULTS: Ten trials have been identified, of which three trials involving 118 @entity0 were included; the dose of @entity7 ranged from 10 to 20 mg/kg/day for up to 12 months. The complex design used in two trials meant that data could only be analysed for subsets of @entity0 . There was no significant difference in weight change, mean difference -0.90 kg (95% confidence interval -1.94 to 0.14) based on 30 @entity0 from two trials. Improvement in biliary excretion was reported in only one trial and no significant change after treatment was shown. There were no data available for analysis for long-term outcomes such as @entity2 or need for liver transplantation. AUTHORS' CONCLUSIONS: There are few trials assessing the effectiveness of @entity7 . There is insufficient evidence to justify its routine use in @entity5 .

title: @entity7 for XXXX .

answer: @entity4


abstract: BACKGROUND: Worldwide, most @entity0 with incurable @entity1 experience @entity3 and @entity4 . These symptoms can @entity2 @entity0 and their family caregivers. Interventions that take account of the relationship between @entity0 and family caregiver may improve outcomes for both members of this dyad. AIM: To report an example of process for the development of a complex intervention, the Family Approach to Weight and Eating. DESIGN: A mixed-methods process informed by the Medical Research Council's guidelines for developing a complex intervention was used to develop a psychosocial intervention for @entity0 with incurable @entity1 and @entity3 or poor appetite and their family caregivers and then to test for its feasibility, acceptability and perceived benefit. SETTING: South of England in 2010/2011. @entity0 : A purposive sample of @entity0 -family caregiver dyads under the care of a specialist community palliative care team. @entity0 @entity0 had incurable @entity1 and were cachectic or at risk of @entity5 . RESULTS: The @entity0 -family caregiver dyads comprised seven female and nine male @entity0 (age range 41-84   years) and their carers. The emergent form of the Family Approach to Weight and Eating was found to aid family talk about food, feelings and reciprocity, without adverse consequences. Of the dyads, 15 reported benefits of the Family Approach to Weight and Eating. Three @entity0 @entity0 spoke of the approach evoking sadness and three carers of guilt. CONCLUSION: The Family Approach to Weight and Eating should now be tested in a pilot trial and the effect on emotional health outcomes in @entity0 and their family caregivers evaluated.

title: A mixed-methods qualitative research study to develop a complex intervention for @entity3 and XXXX in @entity1 : The Family Approach to Weight and Eating.

answer: @entity4


abstract: BACKGROUND: Worldwide, most @entity0 with incurable @entity1 experience @entity3 and @entity4 . These symptoms can @entity2 @entity0 and their family caregivers. Interventions that take account of the relationship between @entity0 and family caregiver may improve outcomes for both members of this dyad. AIM: To report an example of process for the development of a complex intervention, the Family Approach to Weight and Eating. DESIGN: A mixed-methods process informed by the Medical Research Council's guidelines for developing a complex intervention was used to develop a psychosocial intervention for @entity0 with incurable @entity1 and @entity3 or poor appetite and their family caregivers and then to test for its feasibility, acceptability and perceived benefit. SETTING: South of England in 2010/2011. @entity0 : A purposive sample of @entity0 -family caregiver dyads under the care of a specialist community palliative care team. @entity0 @entity0 had incurable @entity1 and were cachectic or at risk of @entity5 . RESULTS: The @entity0 -family caregiver dyads comprised seven female and nine male @entity0 (age range 41-84   years) and their carers. The emergent form of the Family Approach to Weight and Eating was found to aid family talk about food, feelings and reciprocity, without adverse consequences. Of the dyads, 15 reported benefits of the Family Approach to Weight and Eating. Three @entity0 @entity0 spoke of the approach evoking sadness and three carers of guilt. CONCLUSION: The Family Approach to Weight and Eating should now be tested in a pilot trial and the effect on emotional health outcomes in @entity0 and their family caregivers evaluated.

title: A mixed-methods qualitative research study to develop a complex intervention for XXXX and @entity4 in @entity1 : The Family Approach to Weight and Eating.

answer: @entity3


abstract: BACKGROUND: Worldwide, most @entity0 with incurable @entity1 experience @entity3 and @entity4 . These symptoms can @entity2 @entity0 and their family caregivers. Interventions that take account of the relationship between @entity0 and family caregiver may improve outcomes for both members of this dyad. AIM: To report an example of process for the development of a complex intervention, the Family Approach to Weight and Eating. DESIGN: A mixed-methods process informed by the Medical Research Council's guidelines for developing a complex intervention was used to develop a psychosocial intervention for @entity0 with incurable @entity1 and @entity3 or poor appetite and their family caregivers and then to test for its feasibility, acceptability and perceived benefit. SETTING: South of England in 2010/2011. @entity0 : A purposive sample of @entity0 -family caregiver dyads under the care of a specialist community palliative care team. @entity0 @entity0 had incurable @entity1 and were cachectic or at risk of @entity5 . RESULTS: The @entity0 -family caregiver dyads comprised seven female and nine male @entity0 (age range 41-84   years) and their carers. The emergent form of the Family Approach to Weight and Eating was found to aid family talk about food, feelings and reciprocity, without adverse consequences. Of the dyads, 15 reported benefits of the Family Approach to Weight and Eating. Three @entity0 @entity0 spoke of the approach evoking sadness and three carers of guilt. CONCLUSION: The Family Approach to Weight and Eating should now be tested in a pilot trial and the effect on emotional health outcomes in @entity0 and their family caregivers evaluated.

title: A mixed-methods qualitative research study to develop a complex intervention for @entity3 and @entity4 in XXXX : The Family Approach to Weight and Eating.

answer: @entity1


abstract: PURPOSE: Antithyroid drug treatment (ATDT) effectively achieves @entity4 in @entity0 with @entity3 ( @entity3 ). However, apparently successful treatment may be followed by relapse. We investigated the outcome of ATDT in Chinese @entity0 with @entity3 to identify predictive features of relapse. METHODS: In total, 133  @entity0 with mild to moderate @entity6 were included in this analysis. All @entity0 received @entity5 for 12 to 40months and were subsequently followed up for at least 1year. Lasting remission was defined as the presence of clinical and laboratory features of @entity4 for>= 1year after stopping @entity5 . RESULTS: Most @entity0 (118 of 133, 88.7%) remained in remission after the follow-up period; 15  @entity0 (11.3%) developed relapse. A history of @entity3 , larger @entity6 at the time of drug withdrawal, a positive thyroid-stimulating antibody titer and restauration of low thyroid-stimulating hormone levels during the maintenance period were related to a subsequent risk of relapse according to stepwise logistic regression analysis results. However, other clinical and biological features (age, sex, initial @entity6 , @entity7 , @entity2 and @entity1 levels and thyroglobulin antibody and thyroid microsomal antibody titers) did not reach statistical significance. CONCLUSION: Regular, individualized ATDT achieved an 88.7% remission rate in Chinese @entity0 with @entity3 . The features associated with probable relapse were a history of @entity3 , larger @entity6 at the time of drug withdrawal, a positive thyroid-stimulating antibody titer at the time of drug withdrawal and redevelopment of low thyroid-stimulating hormone levels during the maintenance period.

title: Valuable predictive features of relapse of XXXX after antithyroid drug treatment.

answer: @entity3


abstract: UNASSIGNED: Analysis of the immunoglobulin k light chain ( @entity3 ) gene is an alternative method for B-cell clonality assessment in the diagnosis of mature B-cell proliferations in which the detection of clonal @entity6 ( @entity6 ) gene rearrangements fails. The aim of the present study was to evaluate the added value of standardized BIOMED-2 assay for the detection of clonal @entity3 gene rearrangements in the diagnostic setting of suspected @entity4 . With this purpose, 92 specimens from 80 @entity0 with the final diagnosis of @entity4 (37 specimens), @entity2 (26 specimens) and reactive lymphoid proliferation (29 specimens) were analyzed for B-cell clonality. B-cell clonality analysis was performed using the BIOMED-2 @entity6 and @entity3 gene clonality assays. The determined sensitivity of the @entity3 assay was 67.6%, while the determined sensitivity of the @entity6 assay was 75.7%. The sensitivity of combined @entity6 + @entity3 assay was 81.1%. The determined specificity of the @entity3 assay was 96.2% in the group of @entity2 and 96.6% in the group of reactive lesions. The determined specificity of the @entity6 assay was 84.6% in the group of @entity1 and 86.2% in the group of reactive lesions. The comparison of GeneScan (GS) and heteroduplex pretreatment- @entity5 gel electrophoresis (HD-PAGE) methods for the analysis of @entity3 gene rearrangements showed a higher efficacy of GS analysis in a series of 27 @entity4 analyzed by both methods. In the present study, we demonstrated that by applying the combined @entity6 + @entity3 clonality assay the overall detection rate of B-cell clonality was increased by 5.4%. Thus, we confirmed the added value of the standardized BIOMED-2 @entity3 assay for assessment of B-cell clonality in suspected @entity4 with inconclusive clinical and cyto/histological diagnosis.

title: Diagnostic value of immunoglobulin k light chain gene rearrangement analysis in XXXX .

answer: @entity4


abstract: UNASSIGNED: The cellular basis of @entity1 is poorly understood. An important step to understanding this process is to be able to visualize the routes by which @entity2 cells migrate from the @entity2 to various distant sites to eventually form @entity1 . Our laboratory previously developed single-cell in vivo imaging using fluorescent proteins to label @entity2 cells. In the present study, using @entity5 @entity0 @entity4 cells labeled with green fluorescent protein (GFP) and @entity2 transplantation, we have imaged in live @entity3 various highly diverse routes by which @entity5 cells metastasize superiorly and inferiorly to distant sites, including in the portal area, stomach area, and urogenital system. Imaging began at day 9, at which time distant @entity1 had already occurred, and increased at each imaging point at days 10, 13, 14, and 16. Metastatic cells were observed migrating superiorly and inferiorly from the @entity2 as well as in lymphatic channels and trafficking in various organ systems demonstrating that @entity5 has multiple metastatic routes similar to hormone-independent @entity4 in the clinic. J. Cell. Biochem. 117: 1027-1032, 2016.    2015 Wiley Periodicals, Inc.

title: Real Time Metastatic Route Tracking of Orthotopic XXXX -GFP @entity0 Prostate Cancer Using Intravital Imaging.

answer: @entity5


abstract: UNASSIGNED: The cellular basis of @entity1 is poorly understood. An important step to understanding this process is to be able to visualize the routes by which @entity2 cells migrate from the @entity2 to various distant sites to eventually form @entity1 . Our laboratory previously developed single-cell in vivo imaging using fluorescent proteins to label @entity2 cells. In the present study, using @entity5 @entity0 @entity4 cells labeled with green fluorescent protein (GFP) and @entity2 transplantation, we have imaged in live @entity3 various highly diverse routes by which @entity5 cells metastasize superiorly and inferiorly to distant sites, including in the portal area, stomach area, and urogenital system. Imaging began at day 9, at which time distant @entity1 had already occurred, and increased at each imaging point at days 10, 13, 14, and 16. Metastatic cells were observed migrating superiorly and inferiorly from the @entity2 as well as in lymphatic channels and trafficking in various organ systems demonstrating that @entity5 has multiple metastatic routes similar to hormone-independent @entity4 in the clinic. J. Cell. Biochem. 117: 1027-1032, 2016.    2015 Wiley Periodicals, Inc.

title: Real Time Metastatic Route Tracking of Orthotopic @entity5 -GFP XXXX Prostate Cancer Using Intravital Imaging.

answer: @entity0


abstract: BACKGROUND: It is common for @entity0 who die from @entity1 to have a focus on comfort measures at the end of life. The potential role of ethnicity in end-of-life decisions after @entity2 has not been extensively studied. METHODS: @entity0 with @entity1 were prospectively followed in an observational database. Demographic information including ethnicity was collected from medical records and self-reported by @entity0 or their family. Significant in-hospital events including do-not-resuscitate orders, @entity3 ( @entity3 ; care withheld or withdrawn), and mortality were recorded prospectively. RESULTS: 1255 @entity0 were included in our analysis: 650 (52  %) were White, 387 (31  %) Hispanic, and 218 (17  %) Black. Mortality was similar between the groups. @entity3 was more commonly observed in Whites (14  %) compared to either Blacks (10  %) or Hispanics (9  %) (p  =  0.04). In a multivariate analysis controlling for age and Hunt-Hess grade, Hispanics were less likely to have @entity3 than Whites (OR, 0.6; 95  %CI, 0.4-0.9; p  =  0.02). Of the 229 @entity0 who died, 77  % of Whites had @entity3 compared to 54  % of Blacks and 49  % of Hispanics (p  <  0.01). In a multivariate analysis, Blacks (OR, 0.3; 95  %CI, 0.2-0.7; p  <  0.01) and Hispanics (OR, 0.3; 95  %CI, 0.2-0.6; p  <  0.01) were less likely to die with @entity3 orders than Whites. CONCLUSION: After @entity1 , Blacks and Hispanics are less likely to die with @entity3 orders than Whites. Further research to confirm and investigate the causes of these ethnic differences should be performed.

title: Ethnic Disparities in End-of-Life Care After XXXX .

answer: @entity1


abstract: BACKGROUND: Plateau waves in @entity3 ( @entity3 ) are frequently recorded in neuro intensive care and are not yet fully understood. To further investigate this phenomenon, we analyzed partial pressure of cerebral @entity1 (pbtO2) and a moving correlation coefficient between @entity3 and mean arterial blood pressure (ABP), called @entity4 , along with the cerebral @entity1 reactivity index (ORx), which is a moving correlation coefficient between cerebral perfusion pressure (CPP) and pbtO2 in an observational study. METHODS: We analyzed 55 plateau waves in 20 @entity0 after severe @entity2 . We calculated ABP, ABP pulse amplitude (ampABP), @entity3 , CPP, pbtO2, heart rate (HR), @entity3 pulse amplitude (ampICP), @entity4 , and ORx, before, during, and after each plateau wave. The analysis of variance with Bonferroni post hoc test was used to compare the differences in the variables before, during, and after the plateau wave. We considered all plateau waves, even in the same @entity0 , independent because they are separated by long intervals. RESULTS: We found increases for @entity3 and ampICP according to our operational definitions for plateau waves. @entity4 increased significantly (p  =  0.00026), CPP (p  <  0.00001) and pbtO2 (p  =  0.00007) decreased significantly during the plateau waves. ABP, ampABP, and HR remained unchanged. @entity4 during the plateau was higher than before the onset of wave in 40 cases (73  %) with no differences in baseline parameters for those with negative and positive   @entity4 (difference during and after). ORx showed an increase during and a decrease after the plateau waves, however, not statistically significant. PbtO2 overshoot after the wave occurred in 35 times (64  %), the mean difference was 4.9      4.6  Hg (mean      SD), and we found no difference in baseline parameters between those who overshoot and those who did not overshoot. CONCLUSIONS: Arterial blood pressure remains stable in @entity3 plateau waves, while cerebral autoregulatory indices show distinct changes, which indicate cerebrovascular reactivity impairment at the top of the wave. PbtO2 decreases during the waves and may show a slight overshoot after normalization. We assume that this might be due to different latencies of the cerebral blood flow and @entity1 level control mechanisms. Other factors may include baseline conditions, such as pre-plateau wave cerebrovascular reactivity or pbtO2 levels, which differ between studies.

title: Changes in Cerebral Partial XXXX Pressure and Cerebrovascular Reactivity During Intracranial Pressure Plateau Waves.

answer: @entity1


abstract: BACKGROUND:: The effect of urinary alkalinization in cardiac surgery @entity0 at risk of @entity1 ( @entity1 ) is controversial and trial findings conflicting. Accordingly, the authors performed a prospectively planned individual @entity0 data meta-analysis of the double-blind randomized trials in this field. METHODS:: The authors studied 877 @entity0 from three double-blind, randomized controlled trials enrolled to receive either 24 h of intravenous infusion of @entity5 or @entity3 . The primary outcome measure was a postoperative increase in serum @entity2 concentration of greater than 25% or 0.5 mg/dl (> 44  M/L) within the first five postoperative days. Secondary outcomes included the raw change in serum @entity2 , greater than 50% and greater than 100% rises in serum @entity2 , developing @entity1 ( @entity1 ), initiation of renal replacement therapy, morbidity, and mortality. RESULTS:: @entity0 were similar in demographics, comorbidities, and cardiac procedures. @entity5 increased plasma @entity4 (P < 0.001) and urine pH (P < 0.001). There were no differences in the development of the primary outcome ( @entity4 45% [39-51%] vs. Saline 42% [36-48%], P = 0.29). This result remained unchanged when controlling for study and covariates (odds ratio [OR], 99% confidence interval [CI]: @entity4 vs. Control, 1.11 [0.77-1.60], P = 0.45). There was, however, a significant study-adjusted benefit in elective coronary artery bypass surgery @entity0 in terms of renal replacement therapy ( @entity4 vs. Control, OR: 0.38 [99% CI: 0.25-0.58], P < 0.0001) and the development of an @entity1 Network grade = 3 ( @entity4 vs. Control, OR: 0.45 [99% CI: 0.43-0.48], P < 0.0001). CONCLUSIONS:: Urinary alkalinization using @entity5 infusion is not associated with an overall lower incidence of @entity1 ; however, it reduces severe @entity1 and need for renal replacement therapy in elective coronary artery bypass @entity0 .

title: XXXX and Renal Function after Cardiac Surgery: A Prospectively Planned Individual @entity0 Meta-analysis.

answer: @entity5


abstract: BACKGROUND:: The effect of urinary alkalinization in cardiac surgery @entity0 at risk of @entity1 ( @entity1 ) is controversial and trial findings conflicting. Accordingly, the authors performed a prospectively planned individual @entity0 data meta-analysis of the double-blind randomized trials in this field. METHODS:: The authors studied 877 @entity0 from three double-blind, randomized controlled trials enrolled to receive either 24 h of intravenous infusion of @entity5 or @entity3 . The primary outcome measure was a postoperative increase in serum @entity2 concentration of greater than 25% or 0.5 mg/dl (> 44  M/L) within the first five postoperative days. Secondary outcomes included the raw change in serum @entity2 , greater than 50% and greater than 100% rises in serum @entity2 , developing @entity1 ( @entity1 ), initiation of renal replacement therapy, morbidity, and mortality. RESULTS:: @entity0 were similar in demographics, comorbidities, and cardiac procedures. @entity5 increased plasma @entity4 (P < 0.001) and urine pH (P < 0.001). There were no differences in the development of the primary outcome ( @entity4 45% [39-51%] vs. Saline 42% [36-48%], P = 0.29). This result remained unchanged when controlling for study and covariates (odds ratio [OR], 99% confidence interval [CI]: @entity4 vs. Control, 1.11 [0.77-1.60], P = 0.45). There was, however, a significant study-adjusted benefit in elective coronary artery bypass surgery @entity0 in terms of renal replacement therapy ( @entity4 vs. Control, OR: 0.38 [99% CI: 0.25-0.58], P < 0.0001) and the development of an @entity1 Network grade = 3 ( @entity4 vs. Control, OR: 0.45 [99% CI: 0.43-0.48], P < 0.0001). CONCLUSIONS:: Urinary alkalinization using @entity5 infusion is not associated with an overall lower incidence of @entity1 ; however, it reduces severe @entity1 and need for renal replacement therapy in elective coronary artery bypass @entity0 .

title: @entity5 and Renal Function after Cardiac Surgery: A Prospectively Planned Individual XXXX Meta-analysis.

answer: @entity0


abstract: PURPOSE: The optimal management of @entity2 using multimodal @entity6 is a key component of Enhanced Recovery After Surgery (ERAS). @entity1 has adverse clinical implications on postoperative recovery, including prolonging the time to recovery milestones and length of hospital stay. Moreover, the ubiquity of opioids in postoperative analgesic regimens results in adverse effects, such as sedation, @entity4 , urinary retention, ileus, and @entity8 , which can delay discharge. Thus, multimodal @entity6 , i.e., the use of more than one analgesic modality to achieve @entity1 control while reducing opioid-related side effects, has become the cornerstone of enhanced recovery. The purpose of this review is to address the analgesic techniques used as part of multimodal analgesic regimens to optimize @entity2 control and to summarize the evidence for their use in reducing opioid requirements and side effects. PRINCIPAL FINDINGS: There is a wide variety of analgesic techniques available for multimodal postoperative @entity6 . These modalities are divided into pharmacological and non-pharmacological techniques. Systemic pharmacological modalities involve opioids and non-opioids such as @entity7 , non-steroidal anti-inflammatory drugs, @entity3 receptor antagonists, anticonvulsants (e.g., @entity5 analogues), beta-blockers, alpha-2 agonists, transient receptor potential vanilloid receptor agonists ( @entity9 ), and glucocorticoids. Other pharmacological modalities include central neuraxial techniques, surgical-site infiltration, and regional anesthesia. Evidence supports the use of these pharmacological techniques as part of multimodal @entity6 , but each has its own advantages and specific safety profile, which highlights the importance of selecting the appropriate analgesics for each @entity0 . Adjunctive non-pharmacological techniques include acupuncture, music therapy, transcutaneous electrical nerve stimulation, and hypnosis. There is mixed evidence regarding such techniques, although a lack of harm is associated with their use. CONCLUSION: There are continuing advancements in multimodal analgesic techniques; however, @entity2 in general continues to be undermanaged. Furthermore, a continuing challenge in multimodal @entity1 research related to ERAS is the difficulty in carrying out randomized trials to determine the relative importance of any one component, including @entity6 .

title: Optimizing XXXX management to facilitate Enhanced Recovery After Surgery pathways.

answer: @entity1


abstract: A number of a priori @entity1 dosing algorithms, derived using linear regression methods, have been proposed. Although these dosing algorithms may have been validated using @entity0 derived from the same centre, rarely have they been validated using a @entity0 cohort recruited from another centre. In order to undertake external validation, two cohorts were utilised. One cohort formed by @entity0 from a prospective trial and the second formed by @entity0 in the control arm of the EU- @entity2 trial. Of these, 641 @entity0 were identified as having attained stable dosing and formed the dataset used for validation. Predicted maintenance doses from six criterion fulfilling regression models were then compared to individual @entity0 stable @entity1 dose. Predictive ability was assessed with reference to several statistics including the R-square and mean absolute error. The six regression models explained different amounts of variability in the stable maintenance @entity1 dose requirements of the @entity0 in the two validation cohorts; adjusted R-squared values ranged from 24.2% to 68.6%. An overview of the summary statistics demonstrated that no one dosing algorithm could be considered optimal. The larger validation cohort from the prospective trial produced more consistent statistics across the six dosing algorithms. The study found that all the regression models performed worse in the validation cohort when compared to the derivation cohort. Further, there was little difference between regression models that contained pharmacogenetic coefficients and algorithms containing just non-pharmacogenetic coefficients. The inconsistency of results between the validation cohorts suggests that unaccounted population specific factors cause variability in dosing algorithm performance. Better methods for dosing that take into account inter- and intra-individual variability, at the initiation and maintenance phases of @entity1 treatment, are needed.

title: A review of a priori regression models for XXXX maintenance dose prediction.

answer: @entity1


abstract: Three labile @entity1 @entity0 had recurring episodes of altered sensorium. Each had severe @entity3 with superimposed metabolic derangements, including @entity8 , @entity12 without @entity8 , mild @entity13 , and possibly @entity10 . Two of the @entity0 were examined postmortem. Severe @entity9 , basal ganglial calcification and destruction of small intracerebral vessels without evidence of large vessel @entity6 were found unexpectedly in one @entity0 , a rare occurrence in this country although recently reported from Europe. The other @entity0 had large vessel @entity6 only. The clinical expression of the @entity5 was modified by concurrent abnormalities and reflected the sum total of the complexities which coexisted. The pathophysiology of the unconscious state necessarily depends on the inciting factors. @entity7 is associated with @entity4 cerebral @entity2 consumption. Spinal fluid pH is usually maintained during @entity8 but is sometimes lowered inadvertently during @entity11 therapy, with resultant @entity7 . Other variables influencing the clinical expression, with or without @entity8 , would include, among others, blood viscosity alterations, rapid decrements in blood sugar, and existing degrees of @entity14 . The increasing life-span of the juvenile diabetics, favorably influenced by improved management and recently by hemodialysis, may uncover @entity5 heretofore rarely seen and create additional diagnostic and therapeutic enigmas.

title: Cerebral syndromes of XXXX .

answer: @entity1


abstract: Cardiac extracellular matrix (ECM), generated from the process of decellularization, has been widely considered as an ideal source of biological scaffolds. However, current ECM preparations are generally difficult to be applied to generate cardiac tissue. Our research was aimed to improve decellularization protocols to prepare cardiac ECM slices. Adult @entity0 ventricular tissues were embedded in low melting agarose and cut into 300  m slices, and then were divided randomly into three groups: normal cardiac tissue, @entity1 treated group (0.1% @entity1 ) and @entity1 +Triton X-100 treated group (0.1% @entity1 +0.5% Triton X-100). Total RNA content and protein content quantification, HE staining and immunostaining were used to evaluate the removal of cell components and preservation of vital ECM components. Furthermore, @entity0 embryonic stem cell-derived cardiomyocytes (mES-CMs) and @entity0 embryonic fibroblasts (MEFs) were co-cultured with ECM slices to evaluate biocompatibility. The relative residual RNA and protein contents of ECM slices significantly decreased after decellularization. HE staining showed that @entity1 +Triton X-100 treatment better destroyed cellular structure and removed nuclei of ECM slices, compared with @entity1 treatment. Immunostaining showed that collagen IV and laminin were better preserved and presented better similarity to original cardiac tissue in ECM slices acquired by @entity1 +Triton X-100 treatment. However, collagen IV and laminin were significantly decreased and arranged disorderly in @entity1 treated group. We observed effective survival (>=  12 days) of MEFs and mES-CMs on ECM slices acquired by @entity1 +Triton X-100 treatment, and signs of integration, whereas those signs were not found in @entity1 treated group. We concluded that, compared with traditional @entity1 method, new combined protocol ( @entity1 +Triton X-100) generated ECM slices with better component and structural preservation, as well as better biocompatibility.

title: [Acquirement and evaluation of XXXX ventricular extracellular matrix].

answer: @entity0


abstract: AIM: To analyze prognostic factors for survival after transarterial chemoembolization (TACE) combined with microwave ablation (MWA) for @entity3 ( @entity3 ). METHODS: Clinical data of 86 @entity0 who underwent TACE combined with MWA between January 2006 and December 2013 were retrospectively analyzed in this study. Survival curves were detected using log-rank test. Univariate analysis was performed using log-rank test with respect to 13 prognostic factors affecting survival. All statistically significant prognostic factors identified by univariate analysis were entered into a Cox proportion hazards regression model to identify independent predictors of survival. P values were two-sided and P < 0.05 was considered statistically significant. RESULTS: Median follow-up time was 47.6 mo, and median survival time of enrolled @entity0 was 21.5 mo. The 1-, 2-, 3- and 5-year overall survival rates were 72.1%, 44.1%, 31.4% and 13.9%, respectively. @entity1 size(  (2) = 14.999, P = 0.000), @entity2 ( @entity2 ) stage (  (2) = 29.765, P = 0.000), @entity0 -Pugh class (  (2) = 51.820, P = 0.000), portal vein @entity1 thrombus (PVTT) (  (2) = 43.086, P = 0.000), @entity4 (  (2) = 29.791, P = 0.000), MWA therapy times (  (2) = 12.920, P = 0.002), Eastern Cooperative Oncology Group (ECOG) score (  (2) = 28.660, P = 0.000) and targeted drug usage (  (2) = 10.901, P = 0.001) were found to be significantly associated with overall survival by univariate analysis. Multivariate analysis identified that @entity1 size (95%CI: 1.608-4.962, P = 0.000), @entity2 stage (95%CI: 1.016-2.208, P = 0.020), PVTT (95%CI: 2.062-9.068, P = 0.000), MWA therapy times (95%CI: 0.402-0.745, P = 0.000), ECOG score (95%CI: 1.012-3.053, P = 0.045) and targeted drug usage (95%CI: 1.335-3.143, P = 0.001) were independent prognostic factors associated with overall survival. CONCLUSION: Superior performance status, MWA treatment and targeted drug were favorable factors, and large @entity3 , PVTT and advanced @entity2 stage were risk factors for survival after TACE-MWA for @entity3 .

title: Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for XXXX .

answer: @entity3


abstract: UNASSIGNED: Most ionic liquids (ILs) are either water soluble or present a non-negligible miscibility with water that may cause some harmful effects upon their release into the environment. Among other methods, adsorption of ILs onto activated @entity0 (AC) has shown to be an effective technique to remove these compounds from aqueous solutions. However, this method has proved to be viable only for hydrophobic ILs rather than for the hydrophilic that, being water soluble, have a larger tendency for contamination. In this context, an alternative approach using the salting-out ability of inorganic salts is here proposed to enhance the adsorption of hydrophilic ILs onto activated @entity0 . The effect of the concentrations of @entity1 on the adsorption of five ILs onto AC was investigated. A wide range of ILs that allow the inspection of the IL cation family ( @entity2 - and pyridinium-based) and the anion nature (accounting for its hydrophilicity and fluorination) through the adsorption onto AC was studied. In general, it is shown that the use of @entity1 enhances the adsorption of ILs onto AC. In particular, this effect is highly relevant when dealing with hydrophilic ILs that are those that are actually poorly removed by AC. In addition, the COnductor like Screening MOdel for Real Solvents (COSMO-RS) was used aiming at complementing the experimental data obtained. This work contributes with the development of novel methods to remove ILs from water streams aiming at creating "greener" processes.

title: Enhancing the adsorption of ionic liquids onto activated XXXX by the addition of inorganic salts.

answer: @entity0


abstract: BACKGROUND: @entity2 ( @entity2 ) prevalence is increasing in the United States. Mechanical Circulatory Support (MCS) therapy is an option for Advanced @entity2 (AdHF) @entity0 . Perioperatively, @entity1 ( @entity1 ) is linked to the effects of device implantation, augmented by preexisting @entity2 . Early recognition of @entity1 allows for better diagnosis, treatment, and risk prediction. Gene expression profiling (GEP) was used to evaluate clinical phenotypes of peripheral blood mononuclear cells (PBMC) transcriptomes obtained from @entity0 ' blood samples. Whole blood (WB) samples are clinically more feasible, but their performance in comparison to PBMC samples has not been determined. METHODS: We collected blood samples from 31 @entity2 @entity0 (57  15 years old) undergoing cardiothoracic surgery and 7 healthy age-matched controls, between 2010 and 2011, at a single institution. WB and PBMC samples were collected at a single timepoint postoperatively (median day 8 postoperatively) (25-75% IQR 7-14 days) and subjected to Illumina single color @entity0 BeadChip HT12 v4 whole genome expression array analysis. The Sequential Organ Failure Assessment (SOFA) score was used to characterize the severity of @entity1 into low ( <= 4 points), intermediate (5-11), and high (>=  12) risk categories correlating with GEP. RESULTS: Results indicate that the direction of change in GEP of individuals with @entity1 as compared to controls is similar when determined from PBMC versus WB. The main enriched terms by Gene Ontology (GO) analysis included those involved in the inflammatory response, apoptosis, and other stress response related pathways. The data revealed 35 significant GO categories and 26 pathways overlapping between PBMC and WB. Additionally, class prediction using machine learning tools demonstrated that the subset of significant genes shared by PBMC and WB are sufficient to train as a predictor separating the SOFA groups. CONCLUSION: GEP analysis of WB has the potential to become a clinical tool for immune-monitoring in @entity0 with @entity1 .

title: Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in @entity0 with advanced XXXX .

answer: @entity2


abstract: BACKGROUND: @entity2 ( @entity2 ) prevalence is increasing in the United States. Mechanical Circulatory Support (MCS) therapy is an option for Advanced @entity2 (AdHF) @entity0 . Perioperatively, @entity1 ( @entity1 ) is linked to the effects of device implantation, augmented by preexisting @entity2 . Early recognition of @entity1 allows for better diagnosis, treatment, and risk prediction. Gene expression profiling (GEP) was used to evaluate clinical phenotypes of peripheral blood mononuclear cells (PBMC) transcriptomes obtained from @entity0 ' blood samples. Whole blood (WB) samples are clinically more feasible, but their performance in comparison to PBMC samples has not been determined. METHODS: We collected blood samples from 31 @entity2 @entity0 (57  15 years old) undergoing cardiothoracic surgery and 7 healthy age-matched controls, between 2010 and 2011, at a single institution. WB and PBMC samples were collected at a single timepoint postoperatively (median day 8 postoperatively) (25-75% IQR 7-14 days) and subjected to Illumina single color @entity0 BeadChip HT12 v4 whole genome expression array analysis. The Sequential Organ Failure Assessment (SOFA) score was used to characterize the severity of @entity1 into low ( <= 4 points), intermediate (5-11), and high (>=  12) risk categories correlating with GEP. RESULTS: Results indicate that the direction of change in GEP of individuals with @entity1 as compared to controls is similar when determined from PBMC versus WB. The main enriched terms by Gene Ontology (GO) analysis included those involved in the inflammatory response, apoptosis, and other stress response related pathways. The data revealed 35 significant GO categories and 26 pathways overlapping between PBMC and WB. Additionally, class prediction using machine learning tools demonstrated that the subset of significant genes shared by PBMC and WB are sufficient to train as a predictor separating the SOFA groups. CONCLUSION: GEP analysis of WB has the potential to become a clinical tool for immune-monitoring in @entity0 with @entity1 .

title: Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in XXXX with advanced @entity2 .

answer: @entity0


abstract: RATIONALE: Impulsive actions entail (1) capture of the motor system by an action impulse, which is an urge to act and (2) failed suppression of that impulse in order to prevent a response error. Several studies indicate that dopaminergic treatment can induce action impulsivity in @entity0 diagnosed with @entity2 ( @entity2 ). Whether this effect is due to increased impulse expression or to decreased impulse suppression remains to be deciphered. METHOD: We used a novel approach based on electromyographic (EMG) analyses to decipher the effects of the @entity0 's usual dopaminergic therapy on the expression and suppression of subliminal erroneous impulses. To this end, we used a within-subject design and took advantage of the Simon task, that elicits prepotent response tendencies. The @entity0 (N   =   15) performed the task on their usual dopaminergic medication and after complete medication withdrawal (for at least 12  h). RESULTS: The correction rate that measures the ability to suppress subthreshold @entity1 was lower when the @entity0 were on medication as compared to their off medication state (p   <   0.05). The incorrect activation rate that measures the capture of the motor system by action impulses was unaffected by medication. CONCLUSIONS: Dopa therapy affected action impulsivity. Although medication did not influence the incidence of fast action impulses, it significantly reduced @entity0 ' ability to abort and suppress muscle activation related to the incorrect response alternative.

title: Dopa therapy and action impulsivity: subthreshold error activation and suppression in XXXX .

answer: @entity2


abstract: PURPOSE: The purpose of the study was to analyse outcomes with adjuvant concurrent chemoradiotherapy (cCRT) followed by adjuvant chemotherapy (AC) in radically resected @entity2 ( @entity2 ) in Indian @entity0 . METHODS AND MATERIALS: We retrospectively reviewed the records of @entity2 @entity0 who received adjuvant cCRT after extended cholecystectomy (EC) between January 2007 and December 2011. Patterns of recurrence, disease-free survival (DFS), overall survival (OS) and adverse prognostic factors were evaluated. RESULTS: Thirty-two @entity0 were analysed. At a median follow-up of 53  months, 40  % of @entity0 had recurrence either locoregionally (12  %) or had distant metastases (28  %). The 5-year OS and DFS was 25 % and 53  %, respectively. When prognostic factors were evaluated, the median OS was 51 versus 23  months for node-negative (n   =   8) versus node-positive disease (n   =   24), not reached versus 34  months for stage 2 (n   =   4) versus for stage 3 (n   =   28), 46 versus 23  months for R0 (n   =   11) versus R1 resection (n   =   21), 51 versus 12  months (p   =   0.15) for well-differentiated (n   =   16) versus poorly differentiated @entity1 (n   =   8), and 10 versus 51  months for lymphovascular invasion presence (n   =   4) versus absence (n   =   28) (p   =   0.01). CONCLUSION: Outcome in Indian @entity0 with cCRT followed by AC is similar to that reported in the literature. Adjuvant cCRT followed by AC improves outcomes in @entity0 with R1 and node-positive disease. @entity1 , nodal positivity, poor differentiation, presence of perineural invasion and lymphovascular invasion are adverse prognostic features. Further research is required with treatment intensification in @entity0 with adverse prognostic factors to improve outcome.

title: Outcomes of Adjuvant Chemoradiation and Predictors of Survival After Extended Cholecystectomy in XXXX : a Single Institution Experience from an Endemic Region.

answer: @entity2


abstract: Tumor @entity1 factor receptor-associated factor 6 (TRAF6) is a key signaling adaptor molecule for @entity0 @entity1 factor receptor superfamily and Toll-like receptor/interleukin-1 receptor family members. It signals the upstream receptors and is involved in a wide range of biological functions, such as immunity and bone metabolism. In this report, the TRAF6 gene from the pearl oyster Pinctada martensii (designated as PmTRAF6) was identified and characterized. The obtained full-length PmTRAF6 cDNA was 2273 bp, containing a 5'-untranslated region (UTR) of 297 bp, a 3'-UTR of 128 bp with a 42-bp poly (A) tail, and an open reading frame of 1848 bp that encoded 616- @entity3 residues. The deduced protein sequence of PmTRAF6 contained a conserved TRAF family motif including a RING-type @entity2 finger, two TRAF-type @entity2 fingers, and a coiled-coil region followed by one meprin and TRAF homology domain. Multiple-sequence alignment indicated that TRAF6 was highly conserved among species, and PmTRAF6 showed 53% sequence identity to Azumapecten farreri and @entity5 . Furthermore, an @entity3 sequence containing a low-complexity region was inserted in the TRAF6s from mollusk. Quantitative real-time polymerase chain reaction analysis demonstrated that PmTRAF6 was constitutively expressed in all tissues studied, with the most abundant mRNA expression in hepatopancreas and gill in @entity6 . After lipopolysaccharide stimulation, the expression of PmTRAF6 mRNA was dramatically upregulated. These results suggested that the obtained PmTRAF6 was a member of the TRAF6 family and perhaps involved in the @entity4 .

title: Molecular characterization of @entity0 XXXX factor receptor-associated factor 6 (TRAF6) in pearl oyster Pinctada martensii.

answer: @entity1


abstract: Tumor @entity1 factor receptor-associated factor 6 (TRAF6) is a key signaling adaptor molecule for @entity0 @entity1 factor receptor superfamily and Toll-like receptor/interleukin-1 receptor family members. It signals the upstream receptors and is involved in a wide range of biological functions, such as immunity and bone metabolism. In this report, the TRAF6 gene from the pearl oyster Pinctada martensii (designated as PmTRAF6) was identified and characterized. The obtained full-length PmTRAF6 cDNA was 2273 bp, containing a 5'-untranslated region (UTR) of 297 bp, a 3'-UTR of 128 bp with a 42-bp poly (A) tail, and an open reading frame of 1848 bp that encoded 616- @entity3 residues. The deduced protein sequence of PmTRAF6 contained a conserved TRAF family motif including a RING-type @entity2 finger, two TRAF-type @entity2 fingers, and a coiled-coil region followed by one meprin and TRAF homology domain. Multiple-sequence alignment indicated that TRAF6 was highly conserved among species, and PmTRAF6 showed 53% sequence identity to Azumapecten farreri and @entity5 . Furthermore, an @entity3 sequence containing a low-complexity region was inserted in the TRAF6s from mollusk. Quantitative real-time polymerase chain reaction analysis demonstrated that PmTRAF6 was constitutively expressed in all tissues studied, with the most abundant mRNA expression in hepatopancreas and gill in @entity6 . After lipopolysaccharide stimulation, the expression of PmTRAF6 mRNA was dramatically upregulated. These results suggested that the obtained PmTRAF6 was a member of the TRAF6 family and perhaps involved in the @entity4 .

title: Molecular characterization of XXXX @entity1 factor receptor-associated factor 6 (TRAF6) in pearl oyster Pinctada martensii.

answer: @entity0


abstract: BACKGROUND: Late-onset @entity0 (LOS) is among the leading causes of morbidity and mortality in preterm newborns, and currently available diagnostic tools are inadequate. The objective of this study was to evaluate the accuracy of presepsin (P-SEP) as novel biomarker of @entity3 for the diagnosis of LOS in preterm newborns. METHODS: We prospectively studied newborns  <=32 weeks' gestational age with LOS (n = 19) and noninfected controls (n = 21) at 4 to 60 days' postnatal age. At enrollment, and 1, 3, and 5 days later, we ascertained the @entity1 , @entity2 , and P-SEP in the LOS group, whereas P-SEP alone was ascertained in the control group. RESULTS: P-SEP at enrollment was higher in the LOS than the control group (median 1295 vs 562 ng/L, P = .00001) and remained higher throughout the study period. In the LOS group, P-SEP had a borderline reduction at day 1 versus values at enrollment (median 1011 vs 1295 ng/L, P = .05), whereas @entity1 and procalcitonin at day 1 did not differ from baseline values. The receiver operating characteristic curve of P-SEP at enrollment shows an area under the curve of 0.972. The best calculated cutoff value was 885 ng/L, with 94% sensitivity and 100% specificity. Negative likelihood ratio was 0.05, and positive likelihood ratio was infinity. CONCLUSIONS: We demonstrated for the first time in a cohort of preterm newborns that P-SEP is an accurate biomarker for the diagnosis of possible LOS and may also provide useful information for monitoring the response to therapeutic interventions.

title: Presepsin for the detection of late-onset XXXX in preterm newborns.

answer: @entity0


abstract: OBJECTIVE: Test the ability of acidic fluoridated solutions to enhance @entity2 (F) bound on bacteria (1) and the effect of dentifrice consistency on plaque fluid F uptake (2). METHODS: (1) @entity4 isolates were grown in BHI medium (37  C/18h). Bacteria were washed either with @entity1 or @entity3 both at 1mM to remove or add @entity0 , respectively. Pellets were incubated with 12mM @entity5 at pH 4.5 or 7 for 1min and F was quantified in the lysates and supernatants with the electrode, after HMDS-facilitated diffusion. (2) A randomized, double-blind, crossover clinical trial was performed in three phases with nineteen adults (20-35 years) that used one of the dentifrices: commercial toothpaste (1100ppm F, pH7.0 and conventional viscosity (Sorriso Fresh(  ))); experimental liquid dentifrice (ELD) (1100ppm F, pH7.0 and low viscosity [1.1% carboxymethylcellulose (CMC)]) and ELD (1100ppm F and high viscosity pH7.0 (2.2% CMC)). F concentration in plaque fluid was analyzed using an inverted F electrode. RESULTS: (1) Significantly higher F amounts were detected in the lysates of bacteria incubated with @entity5 solution at pH4.5 compared to the supernatant, which was not seen at pH7.0, being this effect @entity0 -dependent. (2) Significantly higher F concentrations in plaque fluid were found 1h after toothbrushing compared to 12h, but no significant differences were seen among the toothpastes. CONCLUSIONS: F at low pH binds more efficiently to @entity4 than at neutral pH and dentifrice viscosity does not interfere in plaque fluid @entity2 incorporation. CLINICAL SIGNIFICANCE: pH of the dentifrice but not consistency may be important to F uptake in plaque.

title: Dentifrice pH but not consistency may affect XXXX uptake in plaque.

answer: @entity2


abstract: UNASSIGNED: Biases in cognition such as Jumping to Conclusions (JTC) and Verbal Self-Monitoring (VSM) are thought to underlie the formation of @entity1 . This prospective study in @entity0 with an @entity3 ( @entity3 ) for @entity1 examined how these cognitive biases changed over time, and predicted clinical and functional outcomes. Twenty-three @entity0 were assessed at clinical presentation and a mean of 31 months later. Performance on a JTC and VSM tasks were measured at both time points. Relationships to symptom severity, level of function and the incidence of @entity2 were then examined. The levels of symptoms, function and VSM all improved over time, while JTC was stable. Five @entity0 (22%) developed a @entity2 during the follow-up period, but the risk of transition was not related to performance on either task at baseline, or to longitudinal changes in task performance. JTC performance correlated with symptom severity at baseline and follow-up. Similarly, performance on the two tasks was not related to the level of functioning at follow-up. Thus, while the @entity3 is associated with both VSM and JTC biases, neither predict the onset of @entity1 or the overall functional outcome.

title: Misattributing speech and jumping to conclusions: A longitudinal study in @entity0 at high risk of XXXX .

answer: @entity1


abstract: UNASSIGNED: Biases in cognition such as Jumping to Conclusions (JTC) and Verbal Self-Monitoring (VSM) are thought to underlie the formation of @entity1 . This prospective study in @entity0 with an @entity3 ( @entity3 ) for @entity1 examined how these cognitive biases changed over time, and predicted clinical and functional outcomes. Twenty-three @entity0 were assessed at clinical presentation and a mean of 31 months later. Performance on a JTC and VSM tasks were measured at both time points. Relationships to symptom severity, level of function and the incidence of @entity2 were then examined. The levels of symptoms, function and VSM all improved over time, while JTC was stable. Five @entity0 (22%) developed a @entity2 during the follow-up period, but the risk of transition was not related to performance on either task at baseline, or to longitudinal changes in task performance. JTC performance correlated with symptom severity at baseline and follow-up. Similarly, performance on the two tasks was not related to the level of functioning at follow-up. Thus, while the @entity3 is associated with both VSM and JTC biases, neither predict the onset of @entity1 or the overall functional outcome.

title: Misattributing speech and jumping to conclusions: A longitudinal study in XXXX at high risk of @entity1 .

answer: @entity0


abstract: BACKGROUND: @entity3 are an important non-motor complication of @entity1 ( @entity1 ) and carry a negative prognosis. Their biological basis is uncertain, but may relate to the activity of resting state networks in brain. We therefore aimed to investigate functional activity of brain in @entity0 with @entity3 (PDVH) in resting state compared to @entity0 without @entity3 (PDnonVH) and a healthy control group (HC). METHODS: Resting state functional MRI was acquired and the primary analysis compared the @entity4 ( @entity4 ) across groups. This informed a secondary analysis, in the @entity1 groups only, comparing functional connectivity between a 'seed' region in the occipital lobe and the rest of the brain. RESULTS: Individuals with PDVH showed lower @entity4 in bilateral lingual gyrus and cuneus and greater @entity4 in temporo-parietal regions, medial temporal gyrus and cerebellum than PDnonVH and HC. PDnonVH also had lower @entity4 in occipitoparietal region and greater @entity4 in medial temporal gyrus, temporo-parietal and cerebellum regions than HC. Functional connectivity analysis revealed that, although both @entity1 groups had lower occipital functional connectivity relative to the HC group, occipital - corticostriatal connectivity was significantly higher in those with PDVH compared with PDnonVH. CONCLUSION: Our study reveals widespread hemodynamic alterations in @entity1 . However, within a functionally abnormal occipital lobe, those with PDVH have even lower @entity4 than non-hallucinators, but have higher occipital functional connectivity with cortical-striatal regions. These findings suggest disruption of pathways underpinning both primary @entity2 may contribute to @entity3 in @entity1 .

title: Resting activity in visual and corticostriatal pathways in XXXX with @entity3 .

answer: @entity1


abstract: BACKGROUND: @entity3 are an important non-motor complication of @entity1 ( @entity1 ) and carry a negative prognosis. Their biological basis is uncertain, but may relate to the activity of resting state networks in brain. We therefore aimed to investigate functional activity of brain in @entity0 with @entity3 (PDVH) in resting state compared to @entity0 without @entity3 (PDnonVH) and a healthy control group (HC). METHODS: Resting state functional MRI was acquired and the primary analysis compared the @entity4 ( @entity4 ) across groups. This informed a secondary analysis, in the @entity1 groups only, comparing functional connectivity between a 'seed' region in the occipital lobe and the rest of the brain. RESULTS: Individuals with PDVH showed lower @entity4 in bilateral lingual gyrus and cuneus and greater @entity4 in temporo-parietal regions, medial temporal gyrus and cerebellum than PDnonVH and HC. PDnonVH also had lower @entity4 in occipitoparietal region and greater @entity4 in medial temporal gyrus, temporo-parietal and cerebellum regions than HC. Functional connectivity analysis revealed that, although both @entity1 groups had lower occipital functional connectivity relative to the HC group, occipital - corticostriatal connectivity was significantly higher in those with PDVH compared with PDnonVH. CONCLUSION: Our study reveals widespread hemodynamic alterations in @entity1 . However, within a functionally abnormal occipital lobe, those with PDVH have even lower @entity4 than non-hallucinators, but have higher occipital functional connectivity with cortical-striatal regions. These findings suggest disruption of pathways underpinning both primary @entity2 may contribute to @entity3 in @entity1 .

title: Resting activity in visual and corticostriatal pathways in @entity1 with XXXX .

answer: @entity3


abstract: UNASSIGNED: @entity0 with @entity2 have a very high mortality. Here we report the first use of a percutaneous pulsatile cardiac assist device, based on a diagonal pump synchronized with the heart cycle by means of an electrocardiographic signal in adult @entity3 . Eight @entity5 underwent mandatory ventilation. During sinus rhythm, there were no differences between pulsatile and nonpulsatile perfusion with regard to pulmonary artery pressure, pulmonary wedge pressure, central venous pressure, mean arterial pressure (MAP), mean pulse pressure, and mean coronary artery flow (CAF). After 2   min of complete @entity1 ( @entity4 ), circulatory support with the i-cor in venoarterial nonpulsatile extracorporeal membrane oxygenation (ECMO) mode (3   L/min) restored systemic circulation, with an increase of MAP to 78.3   mm   Hg and CAF to 5.27   mL/min. After changing from ECMO settings to pulsatile mode (3   L/min, 75   bpm, pulse amplitude range 3500   rpm), MAP did not change significantly (75.6   mm   Hg); however, CAF increased to 8.45   mL/min. After changing back to nonpulsatile mode, MAP remained stable (83.6   mm   Hg), but CAF decreased to 4.85   mL/min. Thereafter, pulsatile cardiac assist was established with a reduced blood flow of 2.5   L/min, and the pulse amplitude range was extended to 4500 rpm. Under these conditions, MAP remained stable (71.0   mm   Hg), but CAF significantly increased to 15.2   mL/min (P   <   0.05). Percutaneous cardiac support using a venoarterial cardiac assist device equipped with a novel diagonal pump is able to restore and increase systemic and coronary circulation during @entity4 . Electrocardiographically triggered synchronized cardiac assist provides an additional increase of coronary artery flow. These promising results are to be confirmed in @entity0 .

title: Pulsatile Venoarterial Perfusion Using a Novel Synchronized Cardiac Assist Device Augments Coronary Artery Blood Flow During XXXX .

answer: @entity4


abstract: UNASSIGNED: Aim: This study aimed to characterize the cellular basis of the @entity5 @entity1 of two novel @entity5 complexes, 3Pt and 1Pt, in comparison with that of @entity4 . 3Pt comprises anionic @entity6 moieties, while 1Pt comprises neutral aromatic ligands. Methods: We compared the cytotoxic potency of 3Pt and 1Pt with that of @entity4 in @entity3 cell lines and an orthotopic @entity0 model. Results: The cytotoxic potency of 3Pt was markedly higher than that of @entity4 in all cell lines. Both novel @entity5 complexes showed a complete lack of cross resistance in @entity4 -resistant cells. @entity8 enhanced the cytotoxic potency of these novel @entity5 complexes, as observed for @entity4 . Apoptosis after drug administration was observed by DNA ladder formation and an @entity9 /PI assay. DNA double-strand breaks were confirmed by phosphorylation of histone H2AX. In vivo, the antitumor activity of 3Pt and 1Pt was superior and similar, respectively, to that of @entity4 . Both novel @entity5 complexes exerted strong antitumor effects on @entity3 in vitro and in vivo. Conclusions: 3Pt may be an effective drug for the treatment of @entity7 because the @entity10 moiety has a high affinity to bone, as exhibited by @entity2 , and is expected to decrease the incidence of side effects at extraskeletal sites and overcome drug resistance. Cationic 1Pt may also be an effective antitumor drug because of its unique chemical structure and properties. Further investigations to detail the antitumor effects of these ionic Pt complexes on @entity3 are warranted.

title: Effectiveness of Two Novel Anionic and Cationic @entity5 Complexes in the Treatment of XXXX .

answer: @entity3


abstract: UNASSIGNED: Aim: This study aimed to characterize the cellular basis of the @entity5 @entity1 of two novel @entity5 complexes, 3Pt and 1Pt, in comparison with that of @entity4 . 3Pt comprises anionic @entity6 moieties, while 1Pt comprises neutral aromatic ligands. Methods: We compared the cytotoxic potency of 3Pt and 1Pt with that of @entity4 in @entity3 cell lines and an orthotopic @entity0 model. Results: The cytotoxic potency of 3Pt was markedly higher than that of @entity4 in all cell lines. Both novel @entity5 complexes showed a complete lack of cross resistance in @entity4 -resistant cells. @entity8 enhanced the cytotoxic potency of these novel @entity5 complexes, as observed for @entity4 . Apoptosis after drug administration was observed by DNA ladder formation and an @entity9 /PI assay. DNA double-strand breaks were confirmed by phosphorylation of histone H2AX. In vivo, the antitumor activity of 3Pt and 1Pt was superior and similar, respectively, to that of @entity4 . Both novel @entity5 complexes exerted strong antitumor effects on @entity3 in vitro and in vivo. Conclusions: 3Pt may be an effective drug for the treatment of @entity7 because the @entity10 moiety has a high affinity to bone, as exhibited by @entity2 , and is expected to decrease the incidence of side effects at extraskeletal sites and overcome drug resistance. Cationic 1Pt may also be an effective antitumor drug because of its unique chemical structure and properties. Further investigations to detail the antitumor effects of these ionic Pt complexes on @entity3 are warranted.

title: Effectiveness of Two Novel Anionic and Cationic XXXX Complexes in the Treatment of @entity3 .

answer: @entity5


abstract: UNASSIGNED: Recent studies with inorganic nanoparticles modified with functional groups have demonstrated improvement in drug delivery into @entity0 cells. In the present study, we prepared, characterized, and evaluated mesoporous @entity6 nanoparticles (MSNs) as carriers for @entity5 (EPI) in order to improve the antitumor efficacy of this drug. MSNs were prepared and functionalized with @entity10 , @entity3 ( @entity4 ) and @entity9 - @entity3 ( @entity7 - @entity4 ) groups. Different nanoparticulate formulations were loaded with EPI. The in vitro @entity1 and the in vivo antitumor efficacy of MSNs containing EPI were evaluated versus free EPI. The EPI release from nanoparticles was shown to be pH-dependent. The size of MSNs functionalized with @entity8 - @entity3 (MSN- @entity7 - @entity4 ) was 123.8  4.8nm. This formulation showed the best antitumor effects at an EPI dose of 9mg/kg in C-26 @entity2 model. The biodistribution results proved that MSN- @entity7 - @entity4 -EPI had a higher @entity0 accumulation compared to free EPI, 3h after drug administration. The results indicated that this formulation could be effective nanocarriers for anti- @entity0 therapies.

title: Surface functionalized mesoporous @entity6 nanoparticles as an effective carrier for XXXX delivery to @entity0 cells.

answer: @entity5


abstract: UNASSIGNED: Recent studies with inorganic nanoparticles modified with functional groups have demonstrated improvement in drug delivery into @entity0 cells. In the present study, we prepared, characterized, and evaluated mesoporous @entity6 nanoparticles (MSNs) as carriers for @entity5 (EPI) in order to improve the antitumor efficacy of this drug. MSNs were prepared and functionalized with @entity10 , @entity3 ( @entity4 ) and @entity9 - @entity3 ( @entity7 - @entity4 ) groups. Different nanoparticulate formulations were loaded with EPI. The in vitro @entity1 and the in vivo antitumor efficacy of MSNs containing EPI were evaluated versus free EPI. The EPI release from nanoparticles was shown to be pH-dependent. The size of MSNs functionalized with @entity8 - @entity3 (MSN- @entity7 - @entity4 ) was 123.8  4.8nm. This formulation showed the best antitumor effects at an EPI dose of 9mg/kg in C-26 @entity2 model. The biodistribution results proved that MSN- @entity7 - @entity4 -EPI had a higher @entity0 accumulation compared to free EPI, 3h after drug administration. The results indicated that this formulation could be effective nanocarriers for anti- @entity0 therapies.

title: Surface functionalized mesoporous XXXX nanoparticles as an effective carrier for @entity5 delivery to @entity0 cells.

answer: @entity6


abstract: UNASSIGNED: Recent studies with inorganic nanoparticles modified with functional groups have demonstrated improvement in drug delivery into @entity0 cells. In the present study, we prepared, characterized, and evaluated mesoporous @entity6 nanoparticles (MSNs) as carriers for @entity5 (EPI) in order to improve the antitumor efficacy of this drug. MSNs were prepared and functionalized with @entity10 , @entity3 ( @entity4 ) and @entity9 - @entity3 ( @entity7 - @entity4 ) groups. Different nanoparticulate formulations were loaded with EPI. The in vitro @entity1 and the in vivo antitumor efficacy of MSNs containing EPI were evaluated versus free EPI. The EPI release from nanoparticles was shown to be pH-dependent. The size of MSNs functionalized with @entity8 - @entity3 (MSN- @entity7 - @entity4 ) was 123.8  4.8nm. This formulation showed the best antitumor effects at an EPI dose of 9mg/kg in C-26 @entity2 model. The biodistribution results proved that MSN- @entity7 - @entity4 -EPI had a higher @entity0 accumulation compared to free EPI, 3h after drug administration. The results indicated that this formulation could be effective nanocarriers for anti- @entity0 therapies.

title: Surface functionalized mesoporous @entity6 nanoparticles as an effective carrier for @entity5 delivery to XXXX cells.

answer: @entity0


abstract: OBJECTIVE: To (1) identify demographic and clinical factors associated with @entity3 ( @entity3 ) in the setting of @entity2 ( @entity2 ) and (2) histologically compare the posterior knee capsule of @entity0 with @entity2 with and without @entity3 . DESIGN: Cross-sectional study. SETTING: Primary care, including private and institutional practice. @entity0 : Thirteen @entity0 with primary @entity2 and @entity3 and 8 @entity0 with primary @entity2 without @entity3 . METHODS: We compared the @entity3 and non- @entity3 groups to identify demographic and clinical factors associated with @entity3 . We examined the histology of the posterior knee capsules of 9 @entity0 with @entity3 and 6 without. MAIN OUTCOME MEASUREMENTS: @entity0 demographic and clinical factors. For histology we measured the proportional composition of collagenous, adipose, and synovial tissues; fibroblast and adipocyte cellularity; and synovial thickness. RESULTS: @entity0 with @entity3 had longer duration of @entity2 , reduced flexion of the surgical knee, and reduced extension of the contralateral knee (P = .04, <.01, and <.01 respectively). Histologically, there was a greater proportion of collagenous tissue and a lower proportion of adipose and synovial tissues in the @entity3 group than in the noncontracture group; however, the differences were not statistically significant. Cellularity was similar between the 2 groups. CONCLUSIONS: Longer duration of knee @entity2 , reduced surgical knee flexion, and reduced contralateral, nonsurgical knee extension were associated with @entity3 in the @entity2 knee undergoing total arthroplasty. Monitoring bilateral knee range of motion in @entity0 with longer-duration @entity2 could allow earlier intervention, reducing functional loss. Capsular tissue composition analysis may indicate a @entity1 process. Further research in which a larger sample size is used will help clarify these novel findings.

title: Knee Flexion Contractures in @entity0 with XXXX : Clinical Features and Histologic Characterization of the Posterior Capsule.

answer: @entity2


abstract: OBJECTIVE: To (1) identify demographic and clinical factors associated with @entity3 ( @entity3 ) in the setting of @entity2 ( @entity2 ) and (2) histologically compare the posterior knee capsule of @entity0 with @entity2 with and without @entity3 . DESIGN: Cross-sectional study. SETTING: Primary care, including private and institutional practice. @entity0 : Thirteen @entity0 with primary @entity2 and @entity3 and 8 @entity0 with primary @entity2 without @entity3 . METHODS: We compared the @entity3 and non- @entity3 groups to identify demographic and clinical factors associated with @entity3 . We examined the histology of the posterior knee capsules of 9 @entity0 with @entity3 and 6 without. MAIN OUTCOME MEASUREMENTS: @entity0 demographic and clinical factors. For histology we measured the proportional composition of collagenous, adipose, and synovial tissues; fibroblast and adipocyte cellularity; and synovial thickness. RESULTS: @entity0 with @entity3 had longer duration of @entity2 , reduced flexion of the surgical knee, and reduced extension of the contralateral knee (P = .04, <.01, and <.01 respectively). Histologically, there was a greater proportion of collagenous tissue and a lower proportion of adipose and synovial tissues in the @entity3 group than in the noncontracture group; however, the differences were not statistically significant. Cellularity was similar between the 2 groups. CONCLUSIONS: Longer duration of knee @entity2 , reduced surgical knee flexion, and reduced contralateral, nonsurgical knee extension were associated with @entity3 in the @entity2 knee undergoing total arthroplasty. Monitoring bilateral knee range of motion in @entity0 with longer-duration @entity2 could allow earlier intervention, reducing functional loss. Capsular tissue composition analysis may indicate a @entity1 process. Further research in which a larger sample size is used will help clarify these novel findings.

title: Knee Flexion Contractures in XXXX with @entity2 : Clinical Features and Histologic Characterization of the Posterior Capsule.

answer: @entity0